Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Markus A. Weigand
 -- 1337 2023-02-16 10:41:52 |
2 format correct
Catherine Yang
 Meta information modification 1337 2023-02-17 01:31:12 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Gallenstein, N.; Tichy, L.; Weigand, M.A.; Schenz, J. Notch Signaling in Inflammatory Diseases. Encyclopedia. Available online: https://encyclopedia.pub/entry/41286 (accessed on 22 November 2024).
Gallenstein N, Tichy L, Weigand MA, Schenz J. Notch Signaling in Inflammatory Diseases. Encyclopedia. Available at: https://encyclopedia.pub/entry/41286. Accessed November 22, 2024.
Gallenstein, Nadia, Lucas Tichy, Markus Alexander Weigand, Judith Schenz. "Notch Signaling in Inflammatory Diseases" Encyclopedia, https://encyclopedia.pub/entry/41286 (accessed November 22, 2024).
Gallenstein, N., Tichy, L., Weigand, M.A., & Schenz, J. (2023, February 16). Notch Signaling in Inflammatory Diseases. In Encyclopedia. https://encyclopedia.pub/entry/41286
Gallenstein, Nadia, et al. "Notch Signaling in Inflammatory Diseases." Encyclopedia. Web. 16 February, 2023.
Notch Signaling in Inflammatory Diseases
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms24043458

Notch signaling, a highly conserved pathway in mammals, is crucial for differentiation and homeostasis of immune cells. The spectrum of diseases is as broad as the cellular functions controlled by Notch signaling. In various types of cancer, cerebrovascular diseases, and inherited disease syndromes, Notch signaling has been found to exert a detrimental impact as well as in inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), primary biliary cirrhosis, and atherosclerosis. 

immune cells immune response Notch therapy

1. Notch Signaling Pathway

In mammals there are four Notch receptors (Notch1-4) and five Notch ligands [Jagged-1, Jagged-2, Delta-like 1 (DLL1), DLL3, and DLL4]. The ligands have both a membrane-bound and soluble form [1]. Both the receptor as well as its ligands are transmembrane proteins with abundant extracellular domains [2]. Ligand binding leads to a conformational change of the receptor and thus facilitates two consecutive proteolytic processes. The first cleavage is arbitrated by the A dys integrin and metalloproteases (ADAM)-family which leads to shedding of the extracellular domain. The second cleavage takes place inside the transmembrane domain and is catalyzed by a γ-secretase complex. The Notch intracellular domain (NICD) is cleaved and subsequently translocates to the nucleus to generate a transactivation complex [3]. This complex is composed of the deoxyribonucleic acid (DNA)-binding C-promoter-binding factor CBF-1 (CSL)/recombination signal-binding protein Jκ (RBP-J), a recombination signal sequence binding protein for Jκ genes) in mammals [4], and Mastermind-like protein (MAML) as a coactivator protein [5]. This process removes co-repressing complexes, mobilizes co-activators such as mastermind proteins, and ultimately leads to transcription of Notch target genes (Figure 1) [2]. The primary Notch target genes include two families of transcriptional factors hairy and enhancer of split (Hes), including HES1 and HES5, and hairy/enhancer-of-split related with YRPW motif (Hey), including HEY1 and HEY2. Other Notch target genes are B Cell lymphoma 1 Protein (BCL-1), cyclin dependent kinase inhibitor (CDKN1A), GATA binding protein 3 (GATA3), and Pre-T cell antigen receptor alpha (PTCRA) [6]. The interaction of Notch receptors with its ligands can be translationally modulated in the Golgi complex by O-linked glycosylation of the receptors. These post-translational modifications are initiated by the enzyme GDP-fucose Protein O-fucosyl transferase 1 (POFUT1), which adds fucose to small cystine-rich motifs called epidermal growth factor (EGF)-like repeats of the Notch extracellular domain. Additional sugar residues can be added to the fucose by glycosyltransferases, including members of the Fringe family proteins. In mammals, there are three Fringe enzymes referred to as Lunatic (Lfng), Manic (Mfng), and Radical Fringe [7]. These Fringe proteins provide for addition of N-acetylglucosamine residues to the glycan chain. Notch receptor glycosylation by Lfng and Mfng results in increased activation by DLL and decreased activation by Jagged ligands, while glycosylation by Radical Fringe enhances activation by all Notch ligands [8]. Besides this canonical Notch pathway, there are RBP-J independent non-canonical Notch signaling pathways [9]. These are reviewed extensively elsewhere [9][10][11][12].
Figure 1. Contact dependent Notch signaling between cells. Ligand binding leads to a conformational change of the receptor. The first cleavage is arbitrated by the ADAM -family which leads to shedding of the extracellular domain. The second cleavage takes place inside the transmembrane domain and is catalyzed by a γ-secretase complex, that discharges the NICD to translocate to the nucleus. Within the nucleus, the NICD binds the DNA-binding protein RBP-J. Binding of NICD leads to transcription of the Notch target genes. Created with BioRender.com.

2. Notch Signaling in Leukemia and Cancer

Notch signaling as an important part of immune regulation was first described in a disease context. Aster et al. discovered that the Notch1 gene leads to T-lineage acute lymphoblastic leukemia (T-ALL) due to (7;9) chromosomal translocation of Notch1 to the TCR loci, inducing the expression of truncated forms of Notch1 [13][14]. The truncation of the Notch1 extracellular domain enables constitutive production of NICD1 in the absence of ligand binding [15][16]. Additionally, activating mutations of Notch3 have been identified by screening primary T-ALL tumors and orthotopic patient-derived xenograft models, even in the absence of activated Notch1 [17].
Since then, Notch signaling has been found to be associated with both pro- and anti-tumorigenic functions in various types of cancers, depending on tissue and cell type [9]. The role of Notch as an oncogene is well characterized for many lymphoid malignancies such as T-ALL, B-chronic lymphocytic leukemia, and splenic marginal zone lymphoma. In contrast, there is increasing evidence that Notch signaling acts as a tumor suppressor in myeloid malignancies [18]. However, in solid tumors such as breast cancer, lung adenocarcinoma, hepatocellular cancer, ovarian cancer, and colorectal cancer activation of Notch has been identified to be oncogenic [19].

3. Notch Signaling in Autoimmune Diseases

Rheumatoid arthritis is an autoimmune disease that primarily affects joints and has a prevalence of approximately 1% of the worldwide population [20]. The impact of Notch on arthritogenic inflammation is multifaceted but governs inflammatory events like endothelial activation, pathologic angiogenesis, as well as leukocyte recruitment, activation, and function. Notch1-initiated signaling participates in hypoxia-induced angiogenesis and conceivably also in VEGF/angiopoietin 2 (VEGF/Ang2)-induced expression of IL-6, IL-8, and Matrix metalloproteinases (MMP) 2 and 9 [21]. Endothelial DLL1 modulates Notch2-mediated differentiation of monocytes involved in both initiation and progression of experimental arthritis [22].
SLE is a systemic autoimmune disease affecting different organ systems due to a deposition of immune complexes activating the complement system [23]. Cleaved Notch1, cleaved Notch2, and Jagged-1 are expressed on podocytes in protein uric nephropathies including lupus nephritis, one of the most serious manifestations of SLE [24]. Stronger mechanistic data revealed that Notch3 affects the progression of nephritis by promoting migration and pro-inflammatory pathways [25]. In line with these findings, constant Notch activation results in podocyte death and it is suggested that Notch acts as a regulator of regeneration in glomerular disorders [26].
SSc is a chronic fibrotic disease of unknown etiology that involves the skin, and diverse internal organs [27]. The resulting fibrosis disturbs the physiological structure of the affected tissues, disrupts proper organ function, and is the major cause of death in SSc patients [27][28]. The Notch pathway is thought to be implicated in the fibrosis that characterizes SSc. Indeed, in the lesioned skin of SSc patients and in their fibroblasts, activated Notch1 can be found [29][30]. Mice with reactive oxygen species (ROS)-induced SSc also display elevated levels of NICD, overexpression of the ligand Jagged-1, and increased transcription of the target gene Hes-1 in the skin and lungs [29]. The Notch pathway is activated in SSc and inhibition of Notch signaling with the γ-secretase inhibitor DAPT exerts potent anti-fibrotic effects in this preclinical model.

4. Notch Signaling in Chronic Inflammation

There are many reports of Notch dysregulation in clinical samples from patients with different chronic inflammatory diseases. In colonic mucosal biopsies from patients with ulcerative colitis, transcription levels of Notch1 and Hes1 were significantly elevated [31]. A gene expression analysis revealed that Jagged-1 is expressed on endothelial cells from patients with giant cell arteritis, but not on endothelial cells from healthy individuals. Moreover, Notch1 was up regulated on circulating CD4+ T cells in these patients [32]. Likewise, in patients with asthma, circulating CD4+ T cells have been found to have higher Notch1 and Notch2 expression levels [33]. Higher levels of active Notch1 have also been observed in human appendix inflammation endothelial cells [34].
Atherosclerosis is an inflammatory disease characterized by the passive accumulation of lipids within artery walls [35]. Modified low-density lipoproteins (LDL), chronic infection, free radicals, or other factors cause a chronic inflammatory process involving the arterial endothelium [36]. Recently it has been shown that Notch signaling is activated in human aortal luminal endothelial cells at atherosclerotic lesions and modulates atherosclerosis by controlling macrophage polarization [37] into a proinflammatory phenotype [38]. Binesh et al. demonstrated in a rat model that enzymatic inhibition of NICD translocation by Diosgenin (a phyto steroid sapogenin) and γ-secretase inhibitor DAPT in differentiating macrophages leads to a significantly decreased NICD expression while at the same time the macrophage marker MAC387 is downregulated [39]. In vitro vascular inflammation models revealed that in different endothelial cells TNF promotes apoptosis through a downregulation of Notch activity. Additionally, it results in a phenotypic switch where Notch4 is replaced by Notch2. Further, Quillard et al. proved a relationship of Notch signaling, caspase activation, and apoptosis in a rat vascular inflammation model [40].

References

  1. Radtke, F.; Fasnacht, N.; MacDonald, H.R. Notch signaling in the immune system. Immunity 2010, 32, 14–27.
  2. Bray, S.J. Notch signalling in context. Nat. Rev. Mol. Cell Biol. 2016, 17, 722–735.
  3. De Strooper, B.; Annaert, W.; Cupers, P.; Saftig, P.; Craessaerts, K.; Mumm, J.S.; Schroeter, E.H.; Schrijvers, V.; Wolfe, M.S.; Ray, W.J.; et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398, 518–522.
  4. Tamura, K.; Taniguchi, Y.; Minoguchi, S.; Sakai, T.; Tun, T.; Furukawa, T.; Honjo, T. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-Jκ/Su(H). Curr. Biol. 1995, 5, 1416–1423.
  5. Petcherski, A.G.; Kimble, J. Mastermind is a putative activator for Notch. Curr. Biol. 2000, 10, R471–R473.
  6. Hildebrand, D.; Uhle, F.; Sahin, D.; Krauser, U.; Weigand, M.A.; Heeg, K. The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes. Front. Cell Infect. Microbiol. 2018, 8, 241.
  7. Kopan, R.; Ilagan, M.X.G. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. Cell 2009, 137, 216–233.
  8. Kakuda, S.; Haltiwanger, R.S. Deciphering the Fringe-mediated Notch Code: Identification of activating and inhibiting sites allowing discrimination between ligands. Dev. Cell 2017, 40, 193.
  9. Ayaz, F.; Osborne, B.A. Non-canonical notch signaling in cancer and immunity. Front. Oncol. 2014, 4, 345.
  10. Layden, M.J.; Martindale, M.Q. Non-canonical Notch signaling represents an ancestral mechanism to regulate neural differentiation. Evodevo 2014, 5, 30.
  11. Liu, L.; Zhang, L.; Zhao, S.; Zhao, X.-Y.; Min, P.-X.; Ma, Y.-D.; Wang, Y.-Y.; Chen, Y.; Tang, S.-J.; Zhang, Y.-J.; et al. Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway. Front. Pharmacol. 2019, 10, 370.
  12. Alfred, V.; Vaccari, T. Mechanisms of Non-canonical Signaling in Health and Disease: Diversity to Take Therapy up a Notch? Adv. Exp. Med. Biol. 2018, 1066, 187–204.
  13. Aster, J.; Pear, W.; Hasserjian, R.; Erba, H.; Davi, F.; Luo, B.; Scott, M.; Baltimore, D.; Sklar, J. Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch. Cold Spring Harb. Symp. Quant. Biol. 1994, 59, 125–136.
  14. Pear, W.S.; Aster, J.C. T cell acute lymphoblastic leukemia/lymphoma: A human cancer commonly associated with aberrant NOTCH1 signaling. Curr. Opin. Hematol. 2004, 11, 426–433.
  15. Ellisen, L.W.; Bird, J.; West, D.C.; Soreng, A.; Reynolds, T.C.; Smith, S.D.; Sklar, J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66, 649–661.
  16. Malecki, M.J.; Sanchez-Irizarry, C.; Mitchell, J.L.; Histen, G.; Xu, M.L.; Aster, J.C.; Blacklow, S.C. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol. Cell. Biol. 2006, 26, 4642–4651.
  17. Bernasconi-Elias, P.; Hu, T.; Jenkins, D.; Firestone, B.; Gans, S.; Kurth, E.; Capodieci, P.; Deplazes-Lauber, J.; Petropoulos, K.; Thiel, P.; et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 2016, 47, 6077–6086.
  18. Lobry, C.; Oh, P.; Mansour, M.; Look, A.T.; Aifantis, I. Notch signaling: Switching an oncogene to a tumor suppressor. Blood 2014, 123, 2451.
  19. Aster, J.C.; Pear, W.S.; Blacklow, S.C. The Varied Roles of Notch in Cancer. Annu. Rev. Pathol. 2017, 12, 245–275.
  20. Scott, D.L.; Wolfe, F.; Huizinga, T.W.J. Rheumatoid arthritis. Lancet 2010, 376, 1094–1108.
  21. Gao, W.; Sweeney, C.; Walsh, C.; Rooney, P.; McCormick, J.; Veale, D.J.; Fearon, U. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann. Rheum. Dis. 2013, 72, 1080–1088.
  22. Misharin, A.V.; Cuda, C.; Saber, R.; Turner, J.; Gierut, A.K.; Haines, G.K.; Berdnikovs, S.; Filer, A.; Clark, A.R.; Buckley, C.D.; et al. Nonclassical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 2014, 9, 591–604.
  23. Paley, M.A.; Strand, V.; Kim, A.H.J. From mechanism to therapies in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2017, 29, 178–186.
  24. Murea, M.; Park, J.-K.; Sharma, S.; Kato, H.; Gruenwald, A.; Niranjan, T.; Si, H.; Thomas, D.B.; Pullman, J.M.; Melamed, M.L.; et al. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int. 2010, 78, 514–522.
  25. El Machhour, F.; Keuylian, Z.; Kavvadas, P.; Dussaule, J.C.; Chatziantoniou, C. Activation of Notch3 in Glomeruli Promotes the Development of Rapidly Progressive Renal Disease. J. Am. Soc. Nephrol. 2015, 26, 1561–1575.
  26. Lasagni, L.; Ballerini, L.; Angelotti, M.L.; Parente, E.; Sagrinati, C.; Mazzinghi, B.; Peired, A.; Ronconi, E.; Becherucci, F.; Bani, D.; et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem. Cells 2010, 28, 1674–1685.
  27. Dees, C.; Zerr, P.; Tomcik, M.; Beyer, C.; Horn, A.; Akhmetshina, A.; Palumbo, K.; Reich, N.; Zwerina, J.; Sticherling, M.; et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis. Rheum. 2011, 63, 1396–1404.
  28. Beyer, C.; Dees, C.; Distler, J.H.W. Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Arch. Dermatol. Res. 2013, 305, 1–8.
  29. Kavian, N.; Servettaz, A.; Mongaret, C.; Wang, A.; Nicco, C.; Chéreau, C.; Grange, P.; Vuiblet, V.; Birembaut, P.; Diebold, M.-D.; et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis. Rheum. 2010, 62, 3477–3487.
  30. Dees, C.; Tomcik, M.; Zerr, P.; Akhmetshina, A.; Horn, A.; Palumbo, K.; Beyer, C.; Zwerina, J.; Distler, O.; Schett, G.; et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann. Rheum. Dis. 2011, 70, 1304–1310.
  31. Ghorbaninejad, M.; Heydari, R.; Mohammadi, P.; Shahrokh, S.; Haghazali, M.; Khanabadi, B.; Meyfour, A. Contribution of NOTCH signaling pathway along with TNF-α in the intestinal inflammation of ulcerative colitis. Gastroenterol. Hepatol. Bed. Bench. 2019, 12 Suppl. 1, S80.
  32. Wen, Z.; Shen, Y.; Berry, G.; Shahram, F.; Li, Y.; Watanabe, R.; Liao, Y.J.; Goronzy, J.J.; Weyand, C.M. The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. Sci. Transl. Med. 2017, 9, eaal3322.
  33. Tindemans, I.; Vroman, H.; Lukkes, M.; van Nimwegen, M.; de Bruijn, M.J.; Li, B.W.; Kleinjan, A.; de Boer, G.M.; Tramper-Stranders, G.A.; Kool, M.; et al. Increased surface expression of NOTCH on memory T cells in peripheral blood from patients with asthma. J. Allergy Clin. Immunol. 2019, 143, 769–771.e3.
  34. Poulsen, L.L.C.; Edelmann, R.J.; Krüger, S.; Diéguez-Hurtado, R.; Shah, A.; Stav-Noraas, T.E.; Renzi, A.; Szymanska, M.; Wang, J.; Ehling, M.; et al. Inhibition of Endothelial NOTCH1 Signaling Attenuates Inflammation by Reducing Cytokine-Mediated Histone Acetylation at Inflammatory Enhancers. Arterioscler. Thromb. Vasc. Biol. 2018, 38, 854–869.
  35. Ross, R. Atherosclerosis—An inflammatory disease. N. Engl. J. Med. 1999, 340, 115–126.
  36. Paoletti, R.; Gotto, A.M.; Hajjar, D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 2004, 109 (Suppl. S1), 23.
  37. Liu, Z.-J.; Tan, Y.; Beecham, G.W.; Seo, D.M.; Tian, R.; Li, Y.; Vazquez-Padron, R.I.; Pericak-Vance, M.; Vance, J.M.; Goldschmidt-Clermont, P.J.; et al. Notch activation induces endothelial cell senescence and pro-inflammatory response: Implication of Notch signaling in atherosclerosis. Atherosclerosis 2012, 225, 296–303.
  38. Sega, F.V.D.; Fortini, F.; Aquila, G.; Campo, G.; Vaccarezza, M.; Rizzo, P. Notch Signaling Regulates Immune Responses in Atherosclerosis. Front. Immunol. 2019, 10, 1130.
  39. Binesh, A.; Devaraj, S.N.; Devaraj, H. Inhibition of nuclear translocation of notch intracellular domain (NICD) by diosgenin prevented atherosclerotic disease progression. Biochimie 2018, 148, 63–71.
  40. Quillard, T.; Devallière, J.; Coupel, S.; Charreau, B. Inflammation dysregulates Notch signaling in endothelial cells: Implication of Notch2 and Notch4 to endothelial dysfunction. Biochem. Pharmacol. 2010, 80, 2032–2041.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cell Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Nadia Gallenstein
,
Lucas Tichy
,
Markus Alexander Weigand
,
Judith Schenz
View Times: 827
Revisions: 2 times (View History)
Update Date: 17 Feb 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback